FSFI endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Bully: Tyler Height: 6'1" Weight: 250 lbs Victim(s): Joe and Dylan Fighter: Daniel Cormier Height: 5'11" Weight: 247 lbs Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing: This episode aired on MTV2 on September 29, 2012. In MTV Latin America, this is run as the first episode of season 3, followed by the "Michael" episode, thus omitting the episode where Mayhem fights Andy.
Stem cell-based therapies: Mesenchymal stem cells or induced pluripotent stem cells (iPSCs) can be differentiated into tenocytes in vitro. These cells offer an almost unlimited source for expanding tendon-like cells, which could be used for tendon repair and regeneration. However, their differentiation protocols still require optimization to achieve functional tenocytes that closely mimic the native tendon environment. Tendon tissue engineering: Combining tenocytes (or stem cells) with biomaterials, such as scaffolds, that mimic the natural tendon extracellular matrix is a promising avenue for tendon repair. These scaffolds can provide structural support and guide the differentiation and organization of tendon cells. Gene editing: Techniques like CRISPR-Cas9 could be used to enhance the tenogenic properties of stem cells or to correct defects in autologous tenocytes derived from the patient's own tissue. This approach could allow for more controlled and efficient tendon regeneration.
== Further reading == Arnold D (2010). "British India and the beri-beri problem". Medical History. 54 (3): 295–314. doi:10.1017/S0025727300004622. PMC 2889456. PMID 20592882. Chisholm H, ed. (1911). "Beri-Beri" . Encyclopædia Britannica. Vol. 03 (11th ed.). Cambridge University Press. pp. 774–775. Smith HA (2017). Forgotten Disease: Illnesses Transformed in Chinese Medicine. doi:10.1093/jhmas/jry029. ISBN 978-1-5036-0350-9. OCLC 993877848.
Sources: en.wikipedia.org
=== Advantages === Cannot revert to virulence meaning they cannot cause the disease they aim to protect against Safe for immunocompromised patients Can withstand changes in conditions (e.g. temperature, light exposure, humidity)
In his home state of Florida, Trump announced he would vote "No" on Amendment 4, an abortion rights referendum, preserving the six-week ban. The announcement came one day after he initially criticized the six-week ban for being "too short" and said he would vote to lengthen it. Trump repeated a false claim that Democrats support abortions after birth and "executing" babies.
Women participated extensively in unconventional warfare, including in combat positions, in the Chinese Red Army during the revolutionary period, Chinese Civil War (1927–1949) and the Second Sino-Japanese War (1937–1945). After the establishment of the People's Republic of China, along with the People's Liberation Army (PLA)'s transition toward the conventional military organization, the role of women in the armed forces gradually reduced to support, medical, and logistics roles. It was considered a prestigious choice for women to join the military. Serving in the military opens up opportunities for education, training, higher status, and relocation to cities after completing the service. During the Cultural Revolution, military service was regarded as a privilege and a method to avoid the Down to the Countryside Movement. In the 1980s, the PLA underwent large-scale demobilization amid the reform and opening up, and women were discharged back to civilian society for economic development while the exclusion of women in the military expanded. In the 1990s, the PLA revived the recruitment of female personnel in regular military formations but primarily focused on non-combat roles at specialized positions. Most women were trained in areas such as academic/engineering, medics, communications, intelligence, cultural work, and administrative work, as these positions conform to the traditional gender roles. Women in the PLA were more likely to be cadets and officers instead of enlisted soldiers because of their specializations.
Sources: en.wikipedia.org
== Safety == Allyl alcohol is hepatotoxic. In rats, in vivo, allyl alcohol is metabolized by liver alcohol dehydrogenase to acrolein, which can cause damage to the microtubules of rat hepatocyte mitochondria and depletion of glutathione. It is significantly more toxic than related alcohols. Its threshold limit value (TLV) is 2 ppm. It is a lachrymator.
Later in the 20th century several British pathologists, Mikey Rochman, Francis Camps, Sydney Smith and Keith Simpson pioneered new forensic science methods. Alec Jeffreys pioneered the use of DNA profiling in forensic science in 1984. He realized the scope of DNA fingerprinting, which uses variations in the genetic code to identify individuals. The method has since become important in forensic science to assist police detective work, and it has also proved useful in resolving paternity and immigration disputes. DNA fingerprinting was first used as a police forensic test to identify the rapist and killer of two teenagers, Lynda Mann and Dawn Ashworth, who were both murdered in Narborough, Leicestershire, in 1983 and 1986 respectively. Colin Pitchfork was identified and convicted of murder after samples taken from him matched semen samples taken from the two dead girls.
Initially, Valve used a hierarchical structure typical of other development firms, driven by the nature of physical game releases through publishers that required tasks to be completed by deadlines. However, as Valve became its own publisher via Steam, it found the hierarchical structure was hindering progress. After completing Half-Life 2, Valve transitioned to a flat organization. Outside of executive management, Valve does not have bosses, and uses an open allocation system. Valve's marketing manager, Doug Lombardi, said: "Nobody writes a design doc and hands it to somebody and says, 'you go build this'. It's the teams that are coming up with the ideas and pushing in the directions that they want to take the product." This approach allows employees to work on whatever interests them, but requires them to take ownership of their product and mistakes they may make, according to Newell. Newell recognized that this structure works well for some but that "there are plenty of great developers for whom this is a terrible place to work". Following the difficult development of Half-Life 2, Newell said he became "obsessed" with improving Valve's work-life balance. Although Valve has no bosses, some employees hold more influence due to seniority or relationships. De facto project leads became "centralized conduits" for organization and sharing information, and decisions are made collectively. Valve uses a process named Overwatch to gather feedback from senior members, which teams may use or ignore. The success of Steam means that Valve is not dependent on the success of its games.
When BRI1 is silenced in tomato, the plants have a similar phenotype to cu3 mutants yet are still able to respond normally to systemin, strengthening the view that BRI1 is not the systemin receptor. In 1994, tomato systemin was found to bind to a 50KDa protein in the cell membrane of tomato. The protein has a structure similar to proteases of the Kex2p-like prohormone convertases. This led Schaller and Ryan to suggest that it is not a receptor, but instead is involved in the processing of ProSys into the active form, or the degradation of Sys. Synthetic forms of tomato systemin, with substituted amino acids at the predicted dibasic cleavage site, remained stable in cell cultures for longer than the native form. Later studies have noted that the enzymes responsible for processing ProSys remain unidentified. No further research has been reported on the 50KDa protein to date, and the gene has not been identified. No receptors for HypSys have so far been reported, but it is thought that they are perceived on the cell membrane by a LRR-RLK. The receptor for AtPep1 has been identified as a 170KDa LRR-RLK and has been named AtPEPR1. AtPep1 is active at 0.1 nano-molar (nM) concentrations and the receptor saturates at 1nM. An analysis of the structure of the AtPEPR1 receptor has shown that it is a member of the LRR XI subfamily of LRR-RLKs in A. thaliana which includes the receptor for another peptide hormone CLAVATA3. Transforming tobacco cell cultures with AtPEPR1 allowed them to respond to AtPep1 in an alkalisation assay, whereas normal tobacco did not show such a response.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.